Cognitive / neuroprotection research
Limited Human Evidence
Region-specific clinical use and research exist. Not an FDA-approved nootropic.
Also known as ACTH(4-10) analog
Synthetic ACTH fragment analog studied as a nootropic/neuroprotective candidate in some countries. Not FDA-approved.
Semax is a synthetic analog of a fragment of adrenocorticotropic hormone. It has been investigated for cognitive and neuroprotection hypotheses, including intranasal use in some research settings. It is not FDA-approved.
Semax is a lab-made relative of a small piece of ACTH, designed not as a steroid-stimulating hormone course but as a CNS research peptide.
Nootropic marketing online is stronger than the independently reviewed U.S. evidence base.
Semax is based on a snippet of a pituitary hormone. Researchers have explored whether it changes brain growth-factor and transmitter signals. That research is not the same as an approved U.S. cognitive drug.
ACTH fragment analogs have been investigated for melanocortin-independent CNS effects, including BDNF-related hypotheses. Exact clinical mechanism and effect size in generalizable trials remain insufficiently established for U.S. practice.
Step 1
Peptide
Semax
Step 2
Proposed targets
CNS signaling hypotheses (including neurotrophic pathways)
Step 3
Pathway
Experimental neuroprotection/cognition models
Step 4
Observed research effect
Investigational; not FDA-established
Region-specific clinical use and research exist. Not an FDA-approved nootropic.
Human studies exist in some literature. They are not presented here as FDA-established indications.
BDNF and monoamine-related hypotheses appear in research summaries; primary papers should be read before any strong mechanistic claim.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Language and publication-bias issues can affect this literature.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete
ACTH fragment analog.
Human studies
in progress
Region-specific literature.
Regulatory status
not started
Not FDA-approved.
No. It is not FDA-approved.
Neurological Research
Synthetic tuftsin-derived heptapeptide studied for anxiolytic and nootropic hypotheses, including work outside the U.S. Not FDA-approved.
View peptide →